IL117320A - PROCESS FOR PURIFYING APOLIPOPROTEINS ApoA AND ApoE OR MIXTURES THEREOF, SUBSTANTIALLY ENDOTOXIN-FREE ApoA OR ApoE PRODUCED BY THIS PROCESS AND THE USE OF APOLIPOPROTEINS PRODUCED BY THIS PROCESS IN THE PREPARATION OF A MEDICAMENT - Google Patents

PROCESS FOR PURIFYING APOLIPOPROTEINS ApoA AND ApoE OR MIXTURES THEREOF, SUBSTANTIALLY ENDOTOXIN-FREE ApoA OR ApoE PRODUCED BY THIS PROCESS AND THE USE OF APOLIPOPROTEINS PRODUCED BY THIS PROCESS IN THE PREPARATION OF A MEDICAMENT

Info

Publication number: IL117320A
Authority: IL; Israel
Prior art keywords: apoa; apoe; matrix; endotoxins; process according
Prior art date: 1995-03-03

Application number

IL11732096A

Other languages

English (en)

Other versions

IL117320A0 (en

Inventor

Hans Ageland

Lena Romander

Original Assignee

Esperion Therapeutics Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1995-03-03

Filing date

1996-02-29

Publication date

2001-06-14

1996-02-29 Application filed by Esperion Therapeutics Inc filed Critical Esperion Therapeutics Inc

1996-06-18 Publication of IL117320A0 publication Critical patent/IL117320A0/xx

2001-06-14 Publication of IL117320A publication Critical patent/IL117320A/en

Links

238000000034 method Methods 0.000 title claims abstract description 76
230000008569 process Effects 0.000 title claims abstract description 50
239000000203 mixture Substances 0.000 title claims abstract description 15
102000007592 Apolipoproteins Human genes 0.000 title claims abstract description 14
108010071619 Apolipoproteins Proteins 0.000 title claims abstract description 14
239000003814 drug Substances 0.000 title claims description 8
102000018619 Apolipoproteins A Human genes 0.000 title description 3
108010027004 Apolipoproteins A Proteins 0.000 title description 3
238000002360 preparation method Methods 0.000 title description 3
102000013918 Apolipoproteins E Human genes 0.000 title 2
108010025628 Apolipoproteins E Proteins 0.000 title 2
239000002158 endotoxin Substances 0.000 claims abstract description 101
101710095339 Apolipoprotein E Proteins 0.000 claims abstract description 73
102100029470 Apolipoprotein E Human genes 0.000 claims abstract description 73
239000011159 matrix material Substances 0.000 claims abstract description 71
239000007864 aqueous solution Substances 0.000 claims abstract description 38
150000001875 compounds Chemical class 0.000 claims abstract description 30
239000004094 surface-active agent Substances 0.000 claims abstract description 27
238000005349 anion exchange Methods 0.000 claims abstract description 25
229910052799 carbon Inorganic materials 0.000 claims abstract description 21
125000004432 carbon atom Chemical group C* 0.000 claims abstract description 21
125000004433 nitrogen atom Chemical group N* 0.000 claims abstract description 21
239000004475 Arginine Substances 0.000 claims description 22
ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims description 22
108010059886 Apolipoprotein A-I Proteins 0.000 claims description 20
102000005666 Apolipoprotein A-I Human genes 0.000 claims description 20
239000000243 solution Chemical group 0.000 claims description 18
ZRALSGWEFCBTJO-UHFFFAOYSA-N Guanidine Chemical compound NC(N)=N ZRALSGWEFCBTJO-UHFFFAOYSA-N 0.000 claims description 12
ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 claims description 9
241000588724 Escherichia coli Species 0.000 claims description 8
XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 claims description 8
239000004202 carbamide Substances 0.000 claims description 8
229920000936 Agarose Polymers 0.000 claims description 6
201000001320 Atherosclerosis Diseases 0.000 claims description 6
208000024172 Cardiovascular disease Diseases 0.000 claims description 6
CHJJGSNFBQVOTG-UHFFFAOYSA-N N-methyl-guanidine Natural products CNC(N)=N CHJJGSNFBQVOTG-UHFFFAOYSA-N 0.000 claims description 6
108020004511 Recombinant DNA Proteins 0.000 claims description 6
SWSQBOPZIKWTGO-UHFFFAOYSA-N dimethylaminoamidine Natural products CN(C)C(N)=N SWSQBOPZIKWTGO-UHFFFAOYSA-N 0.000 claims description 6
238000004519 manufacturing process Methods 0.000 claims description 6
241000894006 Bacteria Species 0.000 claims description 5
230000002829 reductive effect Effects 0.000 claims description 5
150000003839 salts Chemical class 0.000 claims description 3
125000000129 anionic group Chemical group 0.000 claims description 2
238000012360 testing method Methods 0.000 description 46
239000000499 gel Substances 0.000 description 26
239000000872 buffer Substances 0.000 description 24
229920002684 Sepharose Polymers 0.000 description 19
235000018102 proteins Nutrition 0.000 description 19
102000004169 proteins and genes Human genes 0.000 description 19
108090000623 proteins and genes Proteins 0.000 description 19
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 15
235000001014 amino acid Nutrition 0.000 description 11
150000001413 amino acids Chemical class 0.000 description 11
HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 11
150000002632 lipids Chemical class 0.000 description 11
239000012149 elution buffer Substances 0.000 description 9
239000000523 sample Substances 0.000 description 9
238000011068 loading method Methods 0.000 description 8
KXGVEGMKQFWNSR-LLQZFEROSA-N deoxycholic acid Chemical compound C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 KXGVEGMKQFWNSR-LLQZFEROSA-N 0.000 description 7
239000003446 ligand Substances 0.000 description 7
238000005406 washing Methods 0.000 description 7
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
230000003993 interaction Effects 0.000 description 6
GZQKNULLWNGMCW-PWQABINMSA-N lipid A (E. coli) Chemical compound O1[C@H](CO)[C@@H](OP(O)(O)=O)[C@H](OC(=O)C[C@@H](CCCCCCCCCCC)OC(=O)CCCCCCCCCCCCC)[C@@H](NC(=O)C[C@@H](CCCCCCCCCCC)OC(=O)CCCCCCCCCCC)[C@@H]1OC[C@@H]1[C@@H](O)[C@H](OC(=O)C[C@H](O)CCCCCCCCCCC)[C@@H](NC(=O)C[C@H](O)CCCCCCCCCCC)[C@@H](OP(O)(O)=O)O1 GZQKNULLWNGMCW-PWQABINMSA-N 0.000 description 6
230000007246 mechanism Effects 0.000 description 6
QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 5
235000012000 cholesterol Nutrition 0.000 description 5
229960003964 deoxycholic acid Drugs 0.000 description 5
230000000694 effects Effects 0.000 description 5
238000010828 elution Methods 0.000 description 5
239000006167 equilibration buffer Substances 0.000 description 5
238000011084 recovery Methods 0.000 description 5
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
102000004895 Lipoproteins Human genes 0.000 description 4
108090001030 Lipoproteins Proteins 0.000 description 4
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
239000003463 adsorbent Substances 0.000 description 4
230000008901 benefit Effects 0.000 description 4
239000000539 dimer Substances 0.000 description 4
229960004198 guanidine Drugs 0.000 description 4
HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 4
239000007788 liquid Substances 0.000 description 4
229920001184 polypeptide Polymers 0.000 description 4
108090000765 processed proteins & peptides Proteins 0.000 description 4
102000004196 processed proteins & peptides Human genes 0.000 description 4
239000000047 product Substances 0.000 description 4
TYMLOMAKGOJONV-UHFFFAOYSA-N 4-nitroaniline Chemical compound NC1=CC=C([N+]([O-])=O)C=C1 TYMLOMAKGOJONV-UHFFFAOYSA-N 0.000 description 3
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
102000004190 Enzymes Human genes 0.000 description 3
108090000790 Enzymes Proteins 0.000 description 3
241000239218 Limulus Species 0.000 description 3
239000000969 carrier Substances 0.000 description 3
210000004027 cell Anatomy 0.000 description 3
208000029078 coronary artery disease Diseases 0.000 description 3
229940088598 enzyme Drugs 0.000 description 3
238000011067 equilibration Methods 0.000 description 3
235000019441 ethanol Nutrition 0.000 description 3
239000012634 fragment Substances 0.000 description 3
239000012528 membrane Substances 0.000 description 3
239000000178 monomer Substances 0.000 description 3
229920000620 organic polymer Polymers 0.000 description 3
WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 description 3
230000001681 protective effect Effects 0.000 description 3
231100000331 toxic Toxicity 0.000 description 3
230000002588 toxic effect Effects 0.000 description 3
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
108010004103 Chylomicrons Proteins 0.000 description 2
HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 2
102000014190 Phosphatidylcholine-sterol O-acyltransferase Human genes 0.000 description 2
108010011964 Phosphatidylcholine-sterol O-acyltransferase Proteins 0.000 description 2
108010040201 Polymyxins Proteins 0.000 description 2
229920001214 Polysorbate 60 Polymers 0.000 description 2
DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 2
102000003978 Tissue Plasminogen Activator Human genes 0.000 description 2
108090000373 Tissue Plasminogen Activator Proteins 0.000 description 2
125000000217 alkyl group Chemical group 0.000 description 2
238000004458 analytical method Methods 0.000 description 2
239000003242 anti bacterial agent Substances 0.000 description 2
230000027455 binding Effects 0.000 description 2
238000010364 biochemical engineering Methods 0.000 description 2
230000015572 biosynthetic process Effects 0.000 description 2
229920001400 block copolymer Polymers 0.000 description 2
238000006243 chemical reaction Methods 0.000 description 2
238000004587 chromatography analysis Methods 0.000 description 2
239000003593 chromogenic compound Substances 0.000 description 2
229940009976 deoxycholate Drugs 0.000 description 2
238000011161 development Methods 0.000 description 2
230000018109 developmental process Effects 0.000 description 2
239000012153 distilled water Substances 0.000 description 2
150000002194 fatty esters Chemical class 0.000 description 2
150000004676 glycans Chemical class 0.000 description 2
PJJJBBJSCAKJQF-UHFFFAOYSA-N guanidinium chloride Chemical compound [Cl-].NC(N)=[NH2+] PJJJBBJSCAKJQF-UHFFFAOYSA-N 0.000 description 2
125000000623 heterocyclic group Chemical group 0.000 description 2
230000002209 hydrophobic effect Effects 0.000 description 2
229920006008 lipopolysaccharide Polymers 0.000 description 2
239000002245 particle Substances 0.000 description 2
229920001282 polysaccharide Polymers 0.000 description 2
239000005017 polysaccharide Substances 0.000 description 2
229920000136 polysorbate Polymers 0.000 description 2
125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
230000009467 reduction Effects 0.000 description 2
238000009877 rendering Methods 0.000 description 2
125000006850 spacer group Chemical group 0.000 description 2
238000006467 substitution reaction Methods 0.000 description 2
229960000187 tissue plasminogen activator Drugs 0.000 description 2
239000003053 toxin Substances 0.000 description 2
231100000765 toxin Toxicity 0.000 description 2
108700012359 toxins Proteins 0.000 description 2
239000011534 wash buffer Substances 0.000 description 2
WWUZIQQURGPMPG-UHFFFAOYSA-N (-)-D-erythro-Sphingosine Natural products CCCCCCCCCCCCCC=CC(O)C(N)CO WWUZIQQURGPMPG-UHFFFAOYSA-N 0.000 description 1
KILNVBDSWZSGLL-KXQOOQHDSA-N 1,2-dihexadecanoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCC KILNVBDSWZSGLL-KXQOOQHDSA-N 0.000 description 1
102100025573 1-alkyl-2-acetylglycerophosphocholine esterase Human genes 0.000 description 1
PZNPLUBHRSSFHT-RRHRGVEJSA-N 1-hexadecanoyl-2-octadecanoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCCCC(=O)O[C@@H](COP([O-])(=O)OCC[N+](C)(C)C)COC(=O)CCCCCCCCCCCCCCC PZNPLUBHRSSFHT-RRHRGVEJSA-N 0.000 description 1
108010088751 Albumins Proteins 0.000 description 1
102000009027 Albumins Human genes 0.000 description 1
102100037320 Apolipoprotein A-IV Human genes 0.000 description 1
200000000007 Arterial disease Diseases 0.000 description 1
108010024976 Asparaginase Proteins 0.000 description 1
241001529572 Chaceon affinis Species 0.000 description 1
229920002271 DEAE-Sepharose Polymers 0.000 description 1
BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 1
241000196324 Embryophyta Species 0.000 description 1
229930186217 Glycolipid Natural products 0.000 description 1
101000733802 Homo sapiens Apolipoprotein A-I Proteins 0.000 description 1
101000771674 Homo sapiens Apolipoprotein E Proteins 0.000 description 1
102000008100 Human Serum Albumin Human genes 0.000 description 1
108091006905 Human Serum Albumin Proteins 0.000 description 1
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
102000014150 Interferons Human genes 0.000 description 1
108010050904 Interferons Proteins 0.000 description 1
239000012480 LAL reagent Substances 0.000 description 1
SBKRTALNRRAOJP-BWSIXKJUSA-N N-[(2S)-4-amino-1-[[(2S,3R)-1-[[(2S)-4-amino-1-oxo-1-[[(3S,6S,9S,12S,15R,18R,21S)-6,9,18-tris(2-aminoethyl)-15-benzyl-3-[(1R)-1-hydroxyethyl]-12-(2-methylpropyl)-2,5,8,11,14,17,20-heptaoxo-1,4,7,10,13,16,19-heptazacyclotricos-21-yl]amino]butan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-1-oxobutan-2-yl]-6-methylheptanamide (6S)-N-[(2S)-4-amino-1-[[(2S,3R)-1-[[(2S)-4-amino-1-oxo-1-[[(3S,6S,9S,12S,15R,18R,21S)-6,9,18-tris(2-aminoethyl)-15-benzyl-3-[(1R)-1-hydroxyethyl]-12-(2-methylpropyl)-2,5,8,11,14,17,20-heptaoxo-1,4,7,10,13,16,19-heptazacyclotricos-21-yl]amino]butan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-1-oxobutan-2-yl]-6-methyloctanamide sulfuric acid Polymers OS(O)(=O)=O.CC(C)CCCCC(=O)N[C@@H](CCN)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCN)C(=O)N[C@H]1CCNC(=O)[C@@H](NC(=O)[C@H](CCN)NC(=O)[C@H](CCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](Cc2ccccc2)NC(=O)[C@@H](CCN)NC1=O)[C@@H](C)O.CC[C@H](C)CCCCC(=O)N[C@@H](CCN)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCN)C(=O)N[C@H]1CCNC(=O)[C@@H](NC(=O)[C@H](CCN)NC(=O)[C@H](CCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](Cc2ccccc2)NC(=O)[C@@H](CCN)NC1=O)[C@@H](C)O SBKRTALNRRAOJP-BWSIXKJUSA-N 0.000 description 1
229920002302 Nylon 6,6 Polymers 0.000 description 1
239000002202 Polyethylene glycol Substances 0.000 description 1
108010093965 Polymyxin B Proteins 0.000 description 1
206010037660 Pyrexia Diseases 0.000 description 1
241000607142 Salmonella Species 0.000 description 1
229920004890 Triton X-100 Polymers 0.000 description 1
229920004929 Triton X-114 Polymers 0.000 description 1
229940122618 Trypsin inhibitor Drugs 0.000 description 1
102000003990 Urokinase-type plasminogen activator Human genes 0.000 description 1
108090000435 Urokinase-type plasminogen activator Proteins 0.000 description 1
238000002835 absorbance Methods 0.000 description 1
230000004913 activation Effects 0.000 description 1
125000002252 acyl group Chemical group 0.000 description 1
229940050528 albumin Drugs 0.000 description 1
OFHCOWSQAMBJIW-AVJTYSNKSA-N alfacalcidol Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C OFHCOWSQAMBJIW-AVJTYSNKSA-N 0.000 description 1
238000005571 anion exchange chromatography Methods 0.000 description 1
229940088710 antibiotic agent Drugs 0.000 description 1
239000000427 antigen Substances 0.000 description 1
108010073614 apolipoprotein A-IV Proteins 0.000 description 1
150000001483 arginine derivatives Chemical class 0.000 description 1
125000000637 arginyl group Chemical group N[C@@H](CCCNC(N)=N)C(=O)* 0.000 description 1
229960003272 asparaginase Drugs 0.000 description 1
DCXYFEDJOCDNAF-UHFFFAOYSA-M asparaginate Chemical compound [O-]C(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-M 0.000 description 1
230000001580 bacterial effect Effects 0.000 description 1
239000003613 bile acid Substances 0.000 description 1
239000003833 bile salt Substances 0.000 description 1
230000003115 biocidal effect Effects 0.000 description 1
230000004071 biological effect Effects 0.000 description 1
208000002352 blister Diseases 0.000 description 1
239000010836 blood and blood product Substances 0.000 description 1
230000023555 blood coagulation Effects 0.000 description 1
229940125691 blood product Drugs 0.000 description 1
210000001124 body fluid Anatomy 0.000 description 1
239000010839 body fluid Substances 0.000 description 1
210000004899 c-terminal region Anatomy 0.000 description 1
150000001720 carbohydrates Chemical class 0.000 description 1
210000002421 cell wall Anatomy 0.000 description 1
239000013522 chelant Substances 0.000 description 1
239000007795 chemical reaction product Substances 0.000 description 1
230000000052 comparative effect Effects 0.000 description 1
235000005687 corn oil Nutrition 0.000 description 1
235000018417 cysteine Nutrition 0.000 description 1
XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 1
230000009089 cytolysis Effects 0.000 description 1
238000004925 denaturation Methods 0.000 description 1
230000036425 denaturation Effects 0.000 description 1
238000011033 desalting Methods 0.000 description 1
238000001514 detection method Methods 0.000 description 1
235000014113 dietary fatty acids Nutrition 0.000 description 1
229910000397 disodium phosphate Inorganic materials 0.000 description 1
239000008344 egg yolk phospholipid Substances 0.000 description 1
230000008030 elimination Effects 0.000 description 1
238000003379 elimination reaction Methods 0.000 description 1
229930195729 fatty acid Natural products 0.000 description 1
239000000194 fatty acid Substances 0.000 description 1
150000004665 fatty acids Chemical class 0.000 description 1
238000001914 filtration Methods 0.000 description 1
-1 from cells Substances 0.000 description 1
238000007429 general method Methods 0.000 description 1
125000005456 glyceride group Chemical group 0.000 description 1
229960000789 guanidine hydrochloride Drugs 0.000 description 1
125000000487 histidyl group Chemical group [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C([H])=N1 0.000 description 1
102000053020 human ApoE Human genes 0.000 description 1
125000001165 hydrophobic group Chemical group 0.000 description 1
230000002401 inhibitory effect Effects 0.000 description 1
229940079322 interferon Drugs 0.000 description 1
238000010253 intravenous injection Methods 0.000 description 1
230000002427 irreversible effect Effects 0.000 description 1
230000007775 late Effects 0.000 description 1
230000003902 lesion Effects 0.000 description 1
238000012454 limulus amebocyte lysate test Methods 0.000 description 1
230000004576 lipid-binding Effects 0.000 description 1
210000004185 liver Anatomy 0.000 description 1
230000014759 maintenance of location Effects 0.000 description 1
239000000463 material Substances 0.000 description 1
229910052751 metal Inorganic materials 0.000 description 1
239000002184 metal Substances 0.000 description 1
239000000693 micelle Substances 0.000 description 1
230000004048 modification Effects 0.000 description 1
238000012986 modification Methods 0.000 description 1
229910052757 nitrogen Inorganic materials 0.000 description 1
QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
239000002736 nonionic surfactant Substances 0.000 description 1
238000012856 packing Methods 0.000 description 1
230000002093 peripheral effect Effects 0.000 description 1
239000008363 phosphate buffer Substances 0.000 description 1
150000008105 phosphatidylcholines Chemical class 0.000 description 1
150000003904 phospholipids Chemical class 0.000 description 1
230000036470 plasma concentration Effects 0.000 description 1
229920001983 poloxamer Polymers 0.000 description 1
229920001223 polyethylene glycol Polymers 0.000 description 1
229960003548 polymyxin b sulfate Drugs 0.000 description 1
235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
229920001451 polypropylene glycol Polymers 0.000 description 1
239000002243 precursor Substances 0.000 description 1
239000012460 protein solution Substances 0.000 description 1
125000001453 quaternary ammonium group Chemical group 0.000 description 1
230000008929 regeneration Effects 0.000 description 1
239000012557 regeneration buffer Substances 0.000 description 1
238000011069 regeneration method Methods 0.000 description 1
230000000717 retained effect Effects 0.000 description 1
230000004141 reverse cholesterol transport Effects 0.000 description 1
238000004007 reversed phase HPLC Methods 0.000 description 1
239000012488 sample solution Substances 0.000 description 1
229920006395 saturated elastomer Polymers 0.000 description 1
238000000926 separation method Methods 0.000 description 1
238000001612 separation test Methods 0.000 description 1
229910052708 sodium Inorganic materials 0.000 description 1
239000011734 sodium Substances 0.000 description 1
239000011780 sodium chloride Substances 0.000 description 1
239000002195 soluble material Substances 0.000 description 1
239000002904 solvent Substances 0.000 description 1
238000001179 sorption measurement Methods 0.000 description 1
235000012424 soybean oil Nutrition 0.000 description 1
239000003549 soybean oil Substances 0.000 description 1
239000008347 soybean phospholipid Substances 0.000 description 1
238000002798 spectrophotometry method Methods 0.000 description 1
WWUZIQQURGPMPG-KRWOKUGFSA-N sphingosine Chemical compound CCCCCCCCCCCCC\C=C\[C@@H](O)[C@@H](N)CO WWUZIQQURGPMPG-KRWOKUGFSA-N 0.000 description 1
239000007858 starting material Substances 0.000 description 1
239000000126 substance Substances 0.000 description 1
239000000758 substrate Substances 0.000 description 1
239000012085 test solution Substances 0.000 description 1
231100000419 toxicity Toxicity 0.000 description 1
230000001988 toxicity Effects 0.000 description 1
150000003626 triacylglycerols Chemical class 0.000 description 1
239000002753 trypsin inhibitor Substances 0.000 description 1
238000000870 ultraviolet spectroscopy Methods 0.000 description 1
229960005356 urokinase Drugs 0.000 description 1
229940088594 vitamin Drugs 0.000 description 1
239000011782 vitamin Substances 0.000 description 1
235000013343 vitamin Nutrition 0.000 description 1
229930003231 vitamin Natural products 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/775—Apolipopeptides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Organic Chemistry (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Biophysics (AREA)
Genetics & Genomics (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Molecular Biology (AREA)
Biochemistry (AREA)
Gastroenterology & Hepatology (AREA)
Zoology (AREA)
Toxicology (AREA)
Heart & Thoracic Surgery (AREA)
Chemical Kinetics & Catalysis (AREA)
Veterinary Medicine (AREA)
Animal Behavior & Ethology (AREA)
Cardiology (AREA)
Pharmacology & Pharmacy (AREA)
Public Health (AREA)
General Chemical & Material Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Engineering & Computer Science (AREA)
Peptides Or Proteins (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicinal Preparation (AREA)

IL11732096A 1995-03-03 1996-02-29 PROCESS FOR PURIFYING APOLIPOPROTEINS ApoA AND ApoE OR MIXTURES THEREOF, SUBSTANTIALLY ENDOTOXIN-FREE ApoA OR ApoE PRODUCED BY THIS PROCESS AND THE USE OF APOLIPOPROTEINS PRODUCED BY THIS PROCESS IN THE PREPARATION OF A MEDICAMENT IL117320A (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
SE9500778A SE9500778D0 (sv)	1995-03-03	1995-03-03	Process for producing a protein

Publications (2)

Publication Number	Publication Date
IL117320A0 IL117320A0 (en)	1996-06-18
IL117320A true IL117320A (en)	2001-06-14

Family

ID=20397430

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
IL11732096A IL117320A (en)	1995-03-03	1996-02-29	PROCESS FOR PURIFYING APOLIPOPROTEINS ApoA AND ApoE OR MIXTURES THEREOF, SUBSTANTIALLY ENDOTOXIN-FREE ApoA OR ApoE PRODUCED BY THIS PROCESS AND THE USE OF APOLIPOPROTEINS PRODUCED BY THIS PROCESS IN THE PREPARATION OF A MEDICAMENT

Country Status (15)

Country	Link
US (3)	US5834596A (da)
EP (1)	EP0813541B1 (da)
JP (1)	JPH11501046A (da)
AT (1)	ATE240348T1 (da)
AU (1)	AU694623B2 (da)
CA (1)	CA2212125A1 (da)
DE (1)	DE69628148T2 (da)
DK (1)	DK0813541T3 (da)
ES (1)	ES2199284T3 (da)
IL (1)	IL117320A (da)
NZ (1)	NZ303325A (da)
PT (1)	PT813541E (da)
SE (1)	SE9500778D0 (da)
WO (1)	WO1996027608A1 (da)
ZA (1)	ZA961679B (da)

Families Citing this family (56)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
SE9500778D0 (sv) *	1995-03-03	1995-03-03	Pharmacia Ab	Process for producing a protein
SE9603068D0 (sv) *	1996-08-23	1996-08-23	Pharmacia & Upjohn Ab	Process for purifying a protein
SE9603303D0 (sv) *	1996-09-11	1996-09-11	Pharmacia & Upjohn Ab	Process for purifying a protein
SE9603304D0 (sv)	1996-09-11	1996-09-11	Pharmacia & Upjohn Ab	Process for purifying a compound
DE19859703B4 (de) *	1998-12-23	2009-10-29	Macherey, Nagel Gmbh & Co. Handelsgesellschaft	Verfahren zur Aufreinigung von Nukleinsäuren sowie Anionenaustauscher zur Durchführung dieses Verfahrens
US6459003B1 (en)	1999-04-01	2002-10-01	Esperion Therapeutics, Inc.	Ether compounds
US8568766B2 (en)	2000-08-24	2013-10-29	Gattadahalli M. Anantharamaiah	Peptides and peptide mimetics to treat pathologies associated with eye disease
WO2002038609A2 (en) *	2000-11-10	2002-05-16	Proteopharma Aps	Apolipoprotein conjugates
NZ532217A (en) *	2001-09-28	2006-12-22	Esperion Therapeutics Inc	Use of an alpha helical apolipoprotein or HDL associating protein adapted to be administered locally to prevent or reduce stenosis or restenosis or to stabilize a plaque
US20030229062A1 (en) *	2001-12-07	2003-12-11	The Regents Of The University Of California	Treatments for age-related macular degeneration (AMD)
US7470659B2 (en) *	2001-12-07	2008-12-30	The Regents Of The University Of California	Methods to increase reverse cholesterol transport in the retinal pigment epithelium (RPE) and Bruch's membrane (BM)
AU2002360489A1 (en) *	2001-12-07	2003-06-23	The Regents Of The University Of California	Treatment for age-related macular degeneration
CN1668645A (zh) *	2002-05-17	2005-09-14	埃斯佩里安医疗公司	治疗缺血再灌注的方法和组合物
US7335689B2 (en)	2003-01-23	2008-02-26	Esperion Therapeutics, Inc.	Dihydroxyl compounds and compositions for cholesterol management and related uses
TW200526778A (en) *	2003-11-14	2005-08-16	Sembiosys Genetics Inc	Methods for the production of apolipoproteins in transgenic plants
US20050176623A1 (en) *	2004-02-11	2005-08-11	Neil Wagle	Non-invasive treatment of disease using amphipathic compounds
EP1732383A4 (en) *	2004-04-06	2007-05-02	Cedars Sinai Medical Center	PREVENTION AND TREATMENT OF VASCULAR DISEASES WITH RECOMBINANT ADENO ASSOCIATED VIRUS VECTORS THAT CODE APOLIPOPROTEIN A-I AND APOLIPOPROTEIN A-I MILANO
KR100560102B1 (ko) *	2004-06-25	2006-03-13	한국생명공학연구원	프로아포리포단백질 ａ－ⅰ 변이체와, 이를 포함하는고지혈증 또는 동맥경화증 예방 및 치료제
AU2006242651B2 (en)	2005-04-29	2013-05-16	The Regents Of The University Of California	Peptides and peptide mimetics to treat pathologies characterized by an inflammatory response
US20080206142A1 (en) *	2006-06-16	2008-08-28	Lipid Sciences, Inc.	Novel Peptides That Promote Lipid Efflux
US20080227686A1 (en) *	2006-06-16	2008-09-18	Lipid Sciences, Inc.	Novel Peptides that Promote Lipid Efflux
WO2007149355A2 (en) *	2006-06-16	2007-12-27	Lipid Sciences, Inc.	Novel peptides that promote lipid efflux
US9375499B2 (en) *	2006-07-14	2016-06-28	Wisconsin Alumni Research Foundation	Adsorptive membranes for trapping viruses
EP2049137A4 (en)	2006-08-08	2013-05-01	Univ California	SALICYLANILIDES AS AMPLIFIERS OF THE ORAL RELEASE OF THERAPEUTIC PEPTIDES
US20080138284A1 (en) *	2006-09-26	2008-06-12	Lipid Sciences, Inc.	Novel Peptides That Promote Lipid Efflux
US8013122B2 (en) *	2006-12-20	2011-09-06	Kieu Hoang	Method of purifying apolipoprotein A-1
CN100586958C (zh) *	2006-12-20	2010-02-03	上海莱士血液制品股份有限公司	高纯度载脂蛋白a-i的制备方法
JP2010538005A (ja)	2007-08-28	2010-12-09	ユーエービーリサーチファウンデーション	合成アポリポ蛋白質ｅ模倣ポリペプチドおよび使用方法
AU2008296487A1 (en)	2007-08-28	2009-03-12	The Uab Research Foundation	Synthetic apolipoprotein E mimicking polypeptides and methods of use
EP3699172A3 (en)	2008-11-10	2020-11-18	Arbutus Biopharma Corporation	Novel lipids and compositions for the delivery of therapeutics
EP2391343B1 (en)	2009-01-29	2017-03-01	Arbutus Biopharma Corporation	Improved lipid formulation for the delivery of nucleic acids
CA2754043A1 (en)	2009-03-12	2010-09-16	Alnylam Pharmaceuticals, Inc.	Lipid formulated compositions and methods for inhibiting expression of eg5 and vegf genes
CA3042927C (en)	2009-05-05	2022-05-17	Arbutus Biopharma Corporation	Lipid compositions for the delivery of therapeutic agents
KR20220038506A (ko)	2009-06-10	2022-03-28	알닐람 파마슈티칼스 인코포레이티드	향상된 지질 조성물
US9029338B2 (en)	2009-08-14	2015-05-12	Alnylam Pharmaceuticals, Inc.	Lipid formulated compositions and methods for inhibiting expression of a gene from the ebola virus
CA3044884A1 (en)	2009-12-07	2011-06-16	Arbutus Biopharma Corporation	Compositions for nucleic acid delivery
US20130017223A1 (en)	2009-12-18	2013-01-17	The University Of British Columbia	Methods and compositions for delivery of nucleic acids
WO2011139911A2 (en)	2010-04-29	2011-11-10	Isis Pharmaceuticals, Inc.	Lipid formulated single stranded rna
WO2011143362A1 (en)	2010-05-11	2011-11-17	Esperion Therapeutics, Inc.	Dimeric oxidation-resistant apolipoprotein a1 variants
EP4481047A3 (en)	2010-06-03	2025-04-16	Alnylam Pharmaceuticals, Inc.	Biodegradable lipids for the delivery of active agents
WO2012016188A2 (en)	2010-07-30	2012-02-02	Alnylam Pharmaceuticals, Inc.	Methods and compositions for delivery of active agents
WO2012016184A2 (en)	2010-07-30	2012-02-02	Alnylam Pharmaceuticals, Inc.	Methods and compositions for delivery of active agents
US9339513B2 (en)	2010-11-09	2016-05-17	Alnylam Pharmaceuticals, Inc.	Lipid formulated compositions and methods for inhibiting expression of Eg5 and VEGF genes
US9999673B2 (en)	2011-01-11	2018-06-19	Alnylam Pharmaceuticals, Inc.	PEGylated lipids and their use for drug delivery
LT2673296T (lt)	2011-02-07	2019-02-25	Cerenis Therapeutics Holding Sa	Lipoproteino kompleksai ir jų gamyba ir jų panaudojimai
JP6250543B2 (ja)	2011-09-27	2017-12-20	アルニラム・ファーマシューティカルズ・インコーポレーテッド	ジ脂肪族置換ｐｅｇ化脂質
SG11201403207WA (en)	2011-12-12	2014-09-26	Melior Pharmaceuticals I Inc	Treatment of type i and type ii diabetes
WO2013180650A1 (en)	2012-05-31	2013-12-05	Agency For Science, Technology And Research	Methods for reducing levels of protein-contaminant complexes and aggregates in protein preparations by treatment with electropositive organic additives
WO2014011908A1 (en)	2012-07-11	2014-01-16	Esperion Therapeutics, Inc.	Apolipoprotein mixtures
RU2016144908A (ru)	2014-05-02	2018-06-05	Серени Терапеутикс Холдинг Са	Маркеры hdl-терапии
JP7081923B2 (ja)	2014-07-31	2022-06-07	ユーエイビーリサーチファンデーション	アポｅ模倣ペプチド及び血漿コレステロールを取り除くためのより高い効果
MX392182B (es)	2015-03-13	2025-03-21	Esperion Therapeutics Inc	Combinaciones de dosis fija y formulaciones que comprenden ácido 8-hidroxi-2,2,14,14 tetrametilpentadecanodioico (etc1002) y ezetimiba y métodos para tratar o reducir el riesgo de enfermedad cardiovascular.
MA41793A (fr)	2015-03-16	2018-01-23	Esperion Therapeutics Inc	Associations de doses fixes comprenant du etc1002 et une ou plusieurs statines permettant de traiter ou de réduire un risque cardiovasculaire
CN107033237B (zh) *	2017-05-11	2021-07-20	深圳市卫光生物制品股份有限公司	一种人血浆载脂蛋白a-i的分离纯化方法
CN112437765A (zh)	2019-06-21	2021-03-02	艾斯柏伦治疗公司	贝派地酸的盐形式及其使用方法
CA3188232A1 (en) *	2020-08-10	2022-02-17	Kushee-Nidhi Kush KUMAR	Antifungal matrix formed from peptide hydrogels

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JPS6196998A (ja)	1984-10-16	1986-05-15	Mitsubishi Chem Ind Ltd	ヒトアポリポプロテインａ−ｉ様蛋白の産生方法
AU587989B2 (en) *	1984-10-16	1989-09-07	Mitsubishi Chemical Corporation	DMA fragments, expression vectors, proteins, hosts, and process for production of the proteins
SE462100B (sv) *	1985-08-08	1990-05-07	Perstorp Ab	Komposition och dess anvaendning i ett tvaa- eller flerfassystem
EP0262651A3 (en) *	1986-09-30	1990-06-20	Union Carbide Corporation	Isolation of enzyme values from solution
GB8625435D0 (en) *	1986-10-23	1986-11-26	Erba Farmitalia	Human apolipoprotein ai
US5128318A (en) *	1987-05-20	1992-07-07	The Rogosin Institute	Reconstituted HDL particles and uses thereof
GB8712540D0 (en) *	1987-05-28	1987-07-01	Ucb Sa	Expression of human proapolipoprotein a-i
JP2606228B2 (ja) *	1987-09-18	1997-04-30	三菱化学株式会社	ヒトプロアポリポプロテインａ−ｉ様蛋白の産生法
JP2561674B2 (ja)	1987-10-06	1996-12-11	三菱化学株式会社	蛋白質の産生方法
CA1335077C (en) *	1988-02-08	1995-04-04	Henri Isliker	Process for the manufacture of apolipoproteins from human blood plasma or serum
JPH01238534A (ja) *	1988-03-17	1989-09-22	Mitsui Toatsu Chem Inc	エンドトキシンの除去方法
DE68917379T2 (de) *	1988-05-31	1994-12-01	Mitsubishi Chem Ind	Verfahren zur Herstellung von Proteinen, die ähnlich dem natürlich-menschlichen Apolipoprotein-E sind.
DE3819463A1 (de) *	1988-06-08	1989-12-14	Behringwerke Ag	Expressionsvektoren zur herstellung unfusionierter proteine in mikroorganismen
IT1229996B (it) *	1989-04-20	1991-09-20	Cesare Sirtori	Espressione di apolipoproteina ai e apolipoproteina ai-milano in lievito e composizioni farmaceutiche che contengono dette apolipoproteine.
HU214828B (hu) *	1989-10-31	1998-06-29	Schering Corp.	Eljárás heterológ proteinek táptalajba való kiválasztására képes E. coli törzsek előállítására és heterológ proteinek termelésére
SE468881B (sv) *	1991-01-09	1993-04-05	Kabi Pharmacia Ab	Anvaendning av vissa foereningar foer framstaellning av laekemedel foer behandling av endotoxininducerade effekter samt saett att avlaegsna endotoxiner ur diverse loesningar
WO1993000443A1 (en) *	1991-06-26	1993-01-07	Bio-Technology General Corp.	Purification of recombinant apolipoprotein e from bacteria
SE9103701D0 (sv) *	1991-12-13	1991-12-13	Kabi Pharmacia Ab	Apolipoprotein
EP0644897B1 (en) *	1992-06-12	1998-09-16	N.V. Innogenetics S.A.	New peptides and proteins, process for their preparation and their use as cholesterol acceptors
SE9203753D0 (sv) *	1992-12-11	1992-12-11	Kabi Pharmacia Ab	Expression system for producing apolipoprotein ai-m
JP3491917B2 (ja) *	1993-02-05	2004-02-03	メビオール株式会社	熱可逆性ハイドロゲル材料
US5643757A (en) *	1994-03-21	1997-07-01	American Cyanamid Company	High yield production of human apolipoprotein A1 in E. coli.
JP3514514B2 (ja) *	1994-06-14	2004-03-31	財団法人化学及血清療法研究所	ヒト血漿からのアポリポ蛋白ａ−１の製造方法
SE9500724D0 (sv) *	1994-06-23	1995-02-24	Pharmacia Ab	Filtrering
AU3151495A (en) *	1994-08-01	1996-03-04	James T Hsu	Lipoprotein cholesterol assays
SE9500778D0 (sv) *	1995-03-03	1995-03-03	Pharmacia Ab	Process for producing a protein
US5672685A (en) *	1995-10-04	1997-09-30	Duke University	Source of apolipoprotein E and method of isolating apolipoprotein E
SE9603068D0 (sv) *	1996-08-23	1996-08-23	Pharmacia & Upjohn Ab	Process for purifying a protein

1995
- 1995-03-03 SE SE9500778A patent/SE9500778D0/xx unknown
1996
- 1996-02-29 IL IL11732096A patent/IL117320A/en not_active IP Right Cessation
- 1996-03-01 PT PT96906136T patent/PT813541E/pt unknown
- 1996-03-01 DE DE69628148T patent/DE69628148T2/de not_active Expired - Fee Related
- 1996-03-01 AT AT96906136T patent/ATE240348T1/de not_active IP Right Cessation
- 1996-03-01 CA CA002212125A patent/CA2212125A1/en not_active Abandoned
- 1996-03-01 ZA ZA961679A patent/ZA961679B/xx unknown
- 1996-03-01 NZ NZ303325A patent/NZ303325A/xx unknown
- 1996-03-01 US US08/875,125 patent/US5834596A/en not_active Expired - Lifetime
- 1996-03-01 AU AU49607/96A patent/AU694623B2/en not_active Ceased
- 1996-03-01 JP JP8526799A patent/JPH11501046A/ja active Pending
- 1996-03-01 WO PCT/SE1996/000271 patent/WO1996027608A1/en not_active Ceased
- 1996-03-01 EP EP96906136A patent/EP0813541B1/en not_active Expired - Lifetime
- 1996-03-01 DK DK96906136T patent/DK0813541T3/da active
- 1996-03-01 ES ES96906136T patent/ES2199284T3/es not_active Expired - Lifetime
1998
- 1998-08-05 US US09/129,720 patent/US5990081A/en not_active Expired - Lifetime
1999
- 1999-11-22 US US09/444,816 patent/US6506879B1/en not_active Expired - Fee Related

Also Published As

Publication number	Publication date
IL117320A0 (en)	1996-06-18
CA2212125A1 (en)	1996-09-12
EP0813541A1 (en)	1997-12-29
US6506879B1 (en)	2003-01-14
ATE240348T1 (de)	2003-05-15
US5990081A (en)	1999-11-23
ES2199284T3 (es)	2004-02-16
ZA961679B (en)	1996-10-07
JPH11501046A (ja)	1999-01-26
DE69628148T2 (de)	2004-01-08
US5834596A (en)	1998-11-10
WO1996027608A1 (en)	1996-09-12
SE9500778D0 (sv)	1995-03-03
NZ303325A (en)	1998-12-23
DK0813541T3 (da)	2003-09-15
PT813541E (pt)	2003-09-30
AU4960796A (en)	1996-09-23
DE69628148D1 (de)	2003-06-18
AU694623B2 (en)	1998-07-23
EP0813541B1 (en)	2003-05-14

Legal Events

Date	Code	Title
2001-11-25	FF	Patent granted
2002-02-10	KB	Patent renewed
2002-05-23	KB	Patent renewed
2006-04-10	KB	Patent renewed
2010-12-30	MM9K	Patent not in force due to non-payment of renewal fees

Publication	Publication Date	Title
US5834596A (en)	1998-11-10	Process for purifying ApoA or ApoE
US6090921A (en)	2000-07-18	Process for purifying apolipoprotein a or apolipoprotein e
JP2562192B2 (ja)	1996-12-11	血清アルブミンの純化方法
US5672685A (en)	1997-09-30	Source of apolipoprotein E and method of isolating apolipoprotein E
WO1993000443A1 (en)	1993-01-07	Purification of recombinant apolipoprotein e from bacteria
US6559284B1 (en)	2003-05-06	Process for purifying a protein
US5760177A (en)	1998-06-02	Lipopolysaccharide binding protein and process for producing the same
CA2274241C (en)	2003-05-27	A process for purifying apolipoprotein a or apolipoprotein e from human plasma
EP0391974B1 (en)	1993-06-16	Process for the purification of vitamin k-dependent blood clotting factors
KR100361894B1 (ko)	2003-05-12	치환크로마토그라피방법및정제된헤모글로빈생성물
US5445958A (en)	1995-08-29	Process for purifying blood clotting factors
US6414125B1 (en)	2002-07-02	Method of chromatographically purifying or fractionating, respectively, von Willebrand factor from a VWF-containing starting material
JP3514514B2 (ja)	2004-03-31	ヒト血漿からのアポリポ蛋白ａ−１の製造方法
AU4142997A (en)	1998-04-02	A process for purifying apolipoproteins and a composition for use in the proc ess
AU627446C (en)	1995-02-23	Chemical process
AU8418691A (en)	1993-01-25	Purification of recombinant apolipoprotein e from bacteria
CS273467B1 (en)	1991-03-12	Method of precallicreine's and hageman's factor's from blood plasma standard concentrates preparation